Mechanism of Sarcopenia in Heart Failure

NCT ID: NCT05063955

Last Updated: 2023-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-02

Study Completion Date

2033-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 200 consecutive heart failure patients will be included and 50 age and sex-matched individuals with no history of cardiovascular disease will serve as controls.

Baseline variables of body composition, physical capacity, daily physical activity, nutritional status, quality of life, socioeconomic status and insulin resistance will be obtained along with a skeletal muscle tissue biopsy and blood samples for laboratory analyses.

Baseline variables from heart failure patients will be compared to healthy controls.

Patients and controls will be invited to follow-up visits at 12 and 36 months. Changes in baseline variables will be analyzed.

Events will be identified through national registries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Sarcopenia Cachexia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Heart failure Sarcopenia Cachexia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic Heart Failure

Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.

No interventions assigned to this group

Controls

Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ability to provide valid informed consent.
2. Heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.

Exclusion Criteria

1. Cancer requiring treatment (e.g. prostate cancer on watchful waiting does not exclude patients).
2. Severe musculoskeletal or neurological disability.
3. Severe lung disease with a forced expiratory volume 1 \< 40% of predicted. Treatment with anticoagulants (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) is an exclusion criterion for muscle biopsy. Patients with anticoagulant treatment will be invited to participate in the study without muscle biopsy.
4. Other comorbidities that prevent the patient from participating in the study examinations as judged by the investigator.
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aarhus University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Henrik Wiggers

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Henrik Wiggers, Prof.

Role: STUDY_CHAIR

Aarhus University Hospital

Andreas B Tinggaard, MD

Role: STUDY_CHAIR

Aarhus University Hospital

Søren P Johnsen, Prof.

Role: STUDY_CHAIR

Aalborg University Hospital

Helene Nørrelund, Ass. Prof.

Role: STUDY_CHAIR

Aarhus University Hospital

Anders H Larsen, MD, PhD

Role: STUDY_CHAIR

Aarhus University Hospital

Peter Leutscher, Prof.

Role: STUDY_CHAIR

Regionshospital Nordjylland

Peter B Stæhr, MD, PhD

Role: STUDY_CHAIR

Regionshospital Nordjylland

Steen H Jørgensen, MD

Role: STUDY_CHAIR

Regionshospital Nordjylland

Niels Jessen, Prof.

Role: STUDY_CHAIR

Aarhus University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital

Aarhus N, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Henrik Wiggers, Prof.

Role: CONTACT

Phone: +45 2275 3202

Email: [email protected]

Andreas B Tinggaard, MD

Role: CONTACT

Phone: +45 3027 2717

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andreas B Tinggaard, MD

Role: primary

Henrik Wiggers, Prof.

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Tinggaard AB, Sorensen L, Vissing K, Jessen N, Norrelund H, Wiggers H. Daily physical activity and prognostic implications in patients with heart failure: an accelerometer study. Clin Res Cardiol. 2025 May;114(5):616-628. doi: 10.1007/s00392-024-02508-0. Epub 2024 Sep 2.

Reference Type DERIVED
PMID: 39222281 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

73789

Identifier Type: -

Identifier Source: org_study_id